Basel Medical Group Ltd Ordinary Shares (BMGL) Financial Statements

Income statement

Metric	2025	2024	2023	2022
Revenue
Total Revenue	11.3M	10.1M	9.7M	10.7M
Cost of Revenue	2.5M	2.2M	2.3M	2.2M
Gross Profit	8.8M	7.8M	7.4M	8.5M
Operating Expenses
R&D Expense	—	—	—	—
SG&A Expense	6.5M	3.6M	3.3M	4.0M
General & Admin Expense	6.5M	3.6M	3.3M	4.0M
Selling & Marketing Expense	—	—	—	—
Other Expenses	4.4M	2.0M	2.1M	2.0M
Total Operating Expenses	11.0M	5.6M	5.4M	6.0M
Cost and Expenses	13.5M	7.9M	7.7M	8.2M
Operating Income (EBIT)	(2.2M)	2.2M	2.0M	2.5M
Non-Operating
Interest Income	83.3K	—	295.6K	246.7K
Interest Expense	203.9K	176.2K	238.6K	320.9K
Net Interest Income	(120.7K)	(176.2K)	57.0K	(74.2K)
Other Non-Op Income/Expense	(10.3M)	209.4K	128.7K	(87.7K)
Non-Operating Income (excl Interest)	10.1M	(385.7K)	(367.3K)	(233.1K)
EBT (Pre-Tax Income)	(12.5M)	2.4M	2.1M	2.4M
Income Tax Expense	(417.4K)	331.8K	348.3K	408.5K
Bottom Line
Net Income	(12.1M)	2.1M	1.8M	2.0M
Earnings from Cont. Ops	(12.1M)	2.1M	1.8M	2.0M
Earnings from Discont. Ops	—	—	—	—
Bottom Line Net Income	(12.1M)	2.1M	1.8M	2.0M
Per Share
Basic EPS	($5.16)	$1.14	$0.96	$1.07
Diluted EPS	($5.16)	$1.14	$0.96	$1.07
Revenue Per Share	$7.23	$7.42	$7.16	$7.87
Shares
Basic Shares Outstanding	1.6M	1.4M	1.4M	1.4M
Diluted Shares Outstanding	1.6M	1.4M	1.4M	1.4M
Profitability Metrics
EBITDA	(11.1M)	3.1M	2.9M	3.3M
D&A	1.2M	528.7K	557.1K	575.9K
EBIT	(12.3M)	2.6M	2.4M	2.7M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025